FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma
Published 2014 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
FAS-antisense 1 lncRNA and production of soluble versus membrane Fas in B-cell lymphoma
Authors
Keywords
-
Journal
LEUKEMIA
Volume 28, Issue 12, Pages 2376-2387
Publisher
Springer Nature
Online
2014-05-09
DOI
10.1038/leu.2014.126
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Nucleolin inhibits Fas ligand binding and suppresses Fas-mediated apoptosis in vivo via a surface nucleolin-Fas complex
- (2013) J. F. Wise et al. BLOOD
- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
- (2013) Wendy Béguelin et al. CANCER CELL
- B cell receptor signaling in chronic lymphocytic leukemia
- (2013) Jan A. Burger et al. TRENDS IN IMMUNOLOGY
- Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
- (2012) W. Fiskus et al. CLINICAL CANCER RESEARCH
- Targeting B-Cell Receptor Signaling for Anticancer Therapy: The Bruton's Tyrosine Kinase Inhibitor Ibrutinib Induces Impressive Responses in B-Cell Malignancies
- (2012) Adrian Wiestner JOURNAL OF CLINICAL ONCOLOGY
- The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity
- (2012) Jordi Barretina et al. NATURE
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- Plakophilin3 Loss Leads to an Increase in PRL3 Levels Promoting K8 Dephosphorylation, Which Is Required for Transformation and Metastasis
- (2012) Nileema Khapare et al. PLoS One
- Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765
- (2011) S. E. M. Herman et al. BLOOD
- The role of EZH2 in tumour progression
- (2011) C-J Chang et al. BRITISH JOURNAL OF CANCER
- Cancer statistics, 2011
- (2011) Rebecca Siegel et al. CA-A CANCER JOURNAL FOR CLINICIANS
- Aberrations of EZH2 in Cancer
- (2011) A. Chase et al. CLINICAL CANCER RESEARCH
- Predicting protein associations with long noncoding RNAs
- (2011) Matteo Bellucci et al. NATURE METHODS
- EZH2-mediated epigenetic silencing in germinal center B cells contributes to proliferation and lymphomagenesis
- (2010) I. Velichutina et al. BLOOD
- Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation
- (2010) D. B. Yap et al. BLOOD
- Polycomb Group Proteins: Multi-Faceted Regulators of Somatic Stem Cells and Cancer
- (2010) Martin Sauvageau et al. Cell Stem Cell
- Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma
- (2010) R. Eric Davis et al. NATURE
- The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy
- (2010) L. A. Honigberg et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Mechanism of Fas Signaling Regulation by Human Herpesvirus 8 K1 Oncoprotein
- (2009) Z. Berkova et al. JNCI-Journal of the National Cancer Institute
- MYC stimulates EZH2 expression by repression of its negative regulator miR-26a
- (2008) S. Sander et al. BLOOD
- A natural antisense transcript regulates Zeb2/Sip1 gene expression during Snail1-induced epithelial-mesenchymal transition
- (2008) M. Beltran et al. GENES & DEVELOPMENT
- Death by Splicing: Tumor Suppressor RBM5 Freezes Splice-Site Pairing
- (2008) Matthew V. Kotlajich et al. MOLECULAR CELL
- RBM5/Luca-15/H37 Regulates Fas Alternative Splice Site Pairing after Exon Definition
- (2008) Sophie Bonnal et al. MOLECULAR CELL
Add your recorded webinar
Do you already have a recorded webinar? Grow your audience and get more views by easily listing your recording on Peeref.
Upload NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started